CSTL
CSTL
NASDAQ · Health Care

Castle Biosciences Inc

$19.13
+0.25 (+1.32%)
Financial Highlights (FY 2026)
Revenue
379.64M
Net Income
-26,641,796
Gross Margin
79.4%
Profit Margin
-7.0%
Rev Growth
+36.0%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 79.4% 79.4% 47.7% 47.7%
Operating Margin -12.4% -11.2% 15.2% 13.0%
Profit Margin -7.0% -6.7% 8.7% 12.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 379.64M 279.25M 444.03M 500.52M
Gross Profit 301.32M 221.64M 212.01M 238.98M
Operating Income -47,226,917 -31,264,601 67.36M 64.83M
Net Income -26,641,796 -17,637,084 38.68M 60.33M
Gross Margin 79.4% 79.4% 47.7% 47.7%
Operating Margin -12.4% -11.2% 15.2% 13.0%
Profit Margin -7.0% -6.7% 8.7% 12.1%
Rev Growth +36.0% +36.0% +19.0% +24.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 6.30M 6.30M 78.86M 84.01M
Total Equity 283.81M 283.81M 398.79M 356.04M
D/E Ratio 0.02 0.02 0.20 0.24
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -6,409,503 -4,478,873 81.60M 101.87M
Free Cash Flow 45.77M 46.26M